EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

DEVELOPMENTS

17 Drugs in Development

17 Drugs in Development

DIGITAL CONTENT

14 NEWS #PharmaBuzz

media
14 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

17DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lxs196, Lxs-196, 1874276-76-2, Nvp-lxs196, Nvp-lxs-196, Ide196

Molecular Formula

C₂₂H₂₃F₃N₈O

Molecular Weight

472.5 g/mol

InChI Key

XXJXHXJWQSCNPX-UHFFFAOYSA-N

FDA UNII

E0YF0M8O09

Darovasertib is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.

1 2D Structure

Darovasertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide

2.1.2 InChI

InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)

2.1.3 InChI Key

XXJXHXJWQSCNPX-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N

2.2 Other Identifiers

2.2.1 UNII

E0YF0M8O09

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Lxs196

2. Lxs-196

3. 1874276-76-2

4. Nvp-lxs196

5. Nvp-lxs-196

6. Ide196

7. Ide-196

8. Darovasertib [usan]

9. E0yf0m8o09

10. 3-amino-n-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide

11. 3-amino-n-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide

12. 2-pyrazinecarboxamide, 3-amino-n-(3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl)-6-(3-(trifluoromethyl)-2-pyridinyl)-

13. Darovasertib [inn]

14. Unii-e0yf0m8o09

15. Darovasertib [who-dd]

16. Chembl3982723

17. Schembl17506262

18. Gtpl11186

19. Bdbm251460

20. Bcp20781

21. Ex-a2690

22. Zzc27676

23. Nsc800030

24. S6723

25. Zb1591

26. Zinc584641445

27. Cs-7529

28. Nsc-800030

29. Example 9 [wo2016020864a1]

30. Ac-36337

31. Ws-01966

32. Hy-101569

33. D85524

34. Us9452998, 9

35. Q29213686

2.4 Create Date

2016-04-09

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₃F₃N₈O
Molecular Weight	472.5 g/mol
XLogP3	1.9
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	4
Exact Mass	472.19469187 g/mol
Monoisotopic Mass	472.19469187 g/mol
Topological Polar Surface Area	136 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	702
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1